Latest Breaking News On - Chris bunka - Page 12 : comparemela.com

Lexaria Bioscience : Results from Seizure Study Program - Form 8-K

lxrp 8k.htm UNITED STATES SECURITIES AND EXCHANGE. | November 30, 2022

United statesSprague dawleyChris bunkaLexaria bioscience corpSecurities exchangeSeizure study programCommission file numberSecurities exchange actMccurdy roadZip codeSecurities actExchange actPurchase common stockSeizure studyPrincipal executive officerLexaria bioscience corp stock exchange

Lexaria Bioscience progresses with hypertension and oral nicotine studies using DehydraTECH

Lexaria Bioscience progresses with hypertension and oral nicotine studies using DehydraTECH
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Chris bunkaStephen gunnionLexaria bioscience corpLexaria bioscienceIndependent review board

Lexaria s Human Clinical Hypertension Study a Success

Lexaria s Human Clinical Hypertension Study a Success
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Chris bunkaGeorge jurcicLexaria dehydraExchange commissionLexaria bioscience corpCompany or lexariaDrug administrationWall streetLexaria bioscienceBioscience corpPhase ib investigational new drug

Lexaria Welcomes Dr Catherine Turkel to its Board of Directors

Lexaria Welcomes Dr Catherine Turkel to its Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Chris bunkaCatherine turkelGeorge jurcicEledon pharmaceuticalsLexaria bioscience corpDrug administrationTranslational scientific advisory committeeExchange commissionProstate cancer researchCompany or lexariaLexaria bioscienceLexaria boardNezee therapeuticsNovus therapeuticsBoard directorObject pharma

Lexaria Bioscience Corp : Lexaria Welcomes Dr Catherine Turkel to its Board of Directors

KELOWNA, BC / ACCESSWIRE / September 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that

Chris bunkaCatherine turkelGeorge jurcicEledon pharmaceuticalsLexaria bioscience corpDrug administrationTranslational scientific advisory committeeExchange commissionProstate cancer researchCompany or lexariaLexaria bioscienceLexaria boardNezee therapeuticsNovus therapeuticsBoard directorObject pharma